Thursday, April 12, 2018
UPDATE 1-GSK slims portfolio with sale of rare disease gene therapy drugs
LONDON, April 12 (Reuters) - GlaxoSmithKline is divesting its rare disease gene therapy drugs to Orchard Therapeutics, it said on Thursday, as Chief Executive Emma Walmsley makes good on her promise to prune the drugmaker's pharmaceuticals portfolio.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment